{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:19:30Z","timestamp":1787649570304,"version":"build-2736575974"},"reference-count":152,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbamcr.2026.120198","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:15:55Z","timestamp":1784906155000},"page":"120198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-6 family cytokines behind acute COVID-19 and Long COVID syndrome: Mechanisms, biomarkers, and intervention strategies"],"prefix":"10.1016","volume":"1873","author":[{"given":"Matilde","family":"Bustos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Rodr\u00edguez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2026.120198_bb0005","first-page":"102745","article-title":"Coronavirus disease 2019 (COVID-19): multisystem review of pathophysiology","volume":"69","author":"Mir","year":"2021","journal-title":"Ann. Med. Surg. (Lond)"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0015","doi-asserted-by":"crossref","first-page":"1011936","DOI":"10.3389\/fmed.2023.1011936","article-title":"A review of cytokine-based pathophysiology of long COVID symptoms","volume":"10","author":"Low","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0020","doi-asserted-by":"crossref","first-page":"1582783","DOI":"10.3389\/fimmu.2025.1582783","article-title":"Acute COVID-19 and LongCOVID syndrome - molecular implications for therapeutic strategies - review","volume":"16","author":"Michalak","year":"2025","journal-title":"Front. Immunol."},{"issue":"10343","key":"10.1016\/j.bbamcr.2026.120198_bb0025","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/S0140-6736(22)00941-2","article-title":"Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2","volume":"399","author":"Antonelli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0030","article-title":"Global prevalence of long COVID, its subtypes and risk factors: an updated systematic review and meta-analysis","author":"Hou","year":"2025","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/febs.17355","article-title":"More and more pleiotropy within the IL-6 family of cytokines","volume":"292","author":"Rose-John","year":"2025","journal-title":"FEBS J."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41575-021-00473-x","article-title":"New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology","volume":"18","author":"Giraldez","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0045","doi-asserted-by":"crossref","first-page":"891456","DOI":"10.3389\/fimmu.2022.891456","article-title":"Identification of IL-6 signalling components as predictors of severity and outcome in COVID-19","volume":"13","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0050","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620933508","article-title":"Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications","volume":"14","author":"Pelaia","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/biomedicines12030639","article-title":"The role of cytokines and molecular pathways in lung fibrosis following SARS-CoV-2 infection: a physiopathologic (re)view","volume":"12","author":"Lazar","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1395921","article-title":"IL-27 expression regulation and its effects on adaptive immunity against viruses","volume":"15","author":"Andres-Martin","year":"2024","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.bbamcr.2026.120198_bb0070","doi-asserted-by":"crossref","first-page":"11411","DOI":"10.3390\/ijms252111411","article-title":"Cytokine storm in COVID-19: exploring IL-6 signaling and cytokine-microbiome interactions as emerging therapeutic approaches","volume":"25","author":"Paranga","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0075","doi-asserted-by":"crossref","first-page":"e1009128","DOI":"10.1371\/journal.ppat.1009128","article-title":"SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells","volume":"16","author":"Patra","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0080","doi-asserted-by":"crossref","first-page":"1033674","DOI":"10.3389\/fphar.2022.1033674","article-title":"The role of IL-6 in coronavirus, especially in COVID-19","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120198_bb0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120198_bb0090","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0095","article-title":"Regulatory T cells (Tregs) and COVID-19: unveiling the mechanisms, and therapeutic potentialities with a special focus on long COVID","volume":"11","author":"Dhawan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0100","doi-asserted-by":"crossref","first-page":"109130","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0115","doi-asserted-by":"crossref","first-page":"733274","DOI":"10.3389\/fmed.2021.733274","article-title":"Prognostic role and diagnostic power of seven indicators in COVID-19 patients","volume":"8","author":"Ding","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120198_bb0120","article-title":"The value of Interleukin-6 among several inflammatory markers as a predictor of respiratory failure in COVID-19 patients","volume":"11","author":"Fujino","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"7821","key":"10.1016\/j.bbamcr.2026.120198_bb0125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12879-024-10402-3","article-title":"Integration of metabolomics methodologies for the development of predictive models for mortality risk in elderly patients with severe COVID-19","volume":"25","author":"Cui","year":"2025","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0135","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s10517-024-06106-y","article-title":"Factors of Interleukin-6 signaling in COVID-19 patients with lung damage of varying degrees: a pilot study","volume":"176","author":"Korotaeva","year":"2024","journal-title":"Bull. Exp. Biol. Med."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120198_bb0140","article-title":"The behaviour of IL-6 and its soluble receptor complex during different waves of the COVID-19 pandemic","volume":"14","author":"Di Spigna","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0145","doi-asserted-by":"crossref","first-page":"1488745","DOI":"10.3389\/fimmu.2024.1488745","article-title":"Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection","volume":"15","author":"Lokau","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120198_bb0150","doi-asserted-by":"crossref","first-page":"e0304990","DOI":"10.1371\/journal.pone.0304990","article-title":"Inflammatory profiles are associated with long COVID up to 6 months after COVID-19 onset: a prospective cohort study of individuals with mild to critical COVID-19","volume":"19","author":"Wynberg","year":"2024","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0155","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1186\/s12879-024-10222-5","article-title":"Exploring the landscape of symptom-specific inflammatory cytokines in post-COVID syndrome patients","volume":"24","author":"Tilikete","year":"2024","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s43856-025-00829-3","article-title":"Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-na\u00efve individuals with long COVID","volume":"5","author":"Grady","year":"2025","journal-title":"Commun. Med."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0165","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.xcrm.2022.100663","article-title":"The IL-1\u03b2, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19","volume":"3","author":"Schulthei\u00df","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0170","article-title":"Diverse functional autoantibodies in patients with COVID-19","author":"Wang","year":"2021","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0175","doi-asserted-by":"crossref","first-page":"e0283983","DOI":"10.1371\/journal.pone.0283983","article-title":"High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients","volume":"18","author":"Gomes","year":"2023","journal-title":"PloS One"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0180","doi-asserted-by":"crossref","first-page":"1341600","DOI":"10.3389\/fimmu.2024.1341600","article-title":"Pathophysiological, immunological, and inflammatory features of long COVID","volume":"15","author":"Bohmwald","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/ijms27010433","article-title":"Vascular complications of long COVID\u2014from endothelial dysfunction to systemic thrombosis: a systematic review","volume":"27","author":"Stojanovic","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0190","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/ATVBAHA.123.319695","article-title":"Simultaneous targeting of IL-1-signaling and IL-6-trans-signaling preserves human pulmonary endothelial barrier function during a cytokine storm-brief report","volume":"43","author":"Col\u00e1s-Algora","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0195","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jhep.2021.04.050","article-title":"Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy","volume":"75","author":"McConnell","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0200","doi-asserted-by":"crossref","first-page":"105132","DOI":"10.1016\/j.ebiom.2024.105132","article-title":"Targeting IL-6 trans-signalling by sgp130Fc attenuates severity in SARS-CoV-2 -infected mice and reduces endotheliopathy","volume":"103","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2024","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.bbamcr.2026.120198_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178432","article-title":"Redefining normal: cytokine dysregulation in long COVID and the post-pandemic healthy donors","volume":"26","author":"Korobova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pedneo.2020.04.007","article-title":"Interleukin-6 levels in children developing SARS-CoV-2 infection","volume":"61","author":"Soraya","year":"2020","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0215","doi-asserted-by":"crossref","first-page":"100831","DOI":"10.1016\/j.eclinm.2021.100831","article-title":"Reduced inflammatory responses to SARS-CoV-2 infection in children presenting to hospital with COVID-19 in China","volume":"34","author":"Qian","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12519-021-00440-1","article-title":"Characteristics of immune and inflammatory responses among different age groups of pediatric patients with COVID-19 in China","volume":"17","author":"Ji","year":"2021","journal-title":"World J. Pediatr."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s12887-024-05071-9","article-title":"Role of interleukin 6 polymorphism and inflammatory markers in outcome of pediatric Covid- 19 patients","volume":"24","author":"AbdelAziz","year":"2024","journal-title":"BMC Pediatr."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120198_bb0230","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1002\/jmv.27127","article-title":"Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries","volume":"93","author":"Karcioglu Batur","year":"2021","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0235","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s44197-024-00204-w","article-title":"Impacts of inflammatory cytokines variants on systemic inflammatory profile and COVID-19 severity","volume":"14","author":"Deng","year":"2024","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"3\u20134","key":"10.1016\/j.bbamcr.2026.120198_bb0240","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41435-022-00167-7","article-title":"Association of the IL-6R gene polymorphic variant rs2228145(C>A) with IL-6 gene polymorphisms in a healthy cohort of Turkish population","volume":"23","author":"Karc\u0131o\u011flu Batur","year":"2022","journal-title":"Genes Immun."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/iji.12605","article-title":"Genetic polymorphisms of IL6 gene -174G > C and -597G > A are associated with the risk of COVID-19 severity","volume":"50","author":"Verma","year":"2023","journal-title":"Int. J. Immunogenet."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120198_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/v15051197","article-title":"Association of polymorphisms of IL-6 pathway genes (IL6, IL6R and IL6ST) with COVID-19 severity in an Amazonian population","volume":"15","author":"Rodrigues","year":"2023","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0255","first-page":"548","article-title":"Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia","volume":"155","author":"Ulhaq","year":"2020","journal-title":"Med. Clin. (Engl. Ed)"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0260","doi-asserted-by":"crossref","first-page":"156445","DOI":"10.1016\/j.cyto.2023.156445","article-title":"Impact of IL-6 rs1800795 and IL-17A rs2275913 gene polymorphisms on the COVID-19 prognosis and susceptibility in a sample of Iranian patients","volume":"174","author":"Khafaei","year":"2024","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0265","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12879-025-10695-y","article-title":"High nasopharyngeal and serum IL-6 levels and the -573G>C polymorphism (rs1800796) are linked with the risk of severe COVID-19 in a Mexican population: a case\u2013control study","volume":"25","author":"Torres-Poveda","year":"2025","journal-title":"BMC Infect. Dis."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0270","article-title":"Analysis of gene single nucleotide polymorphisms in COVID-19 disease highlighting the susceptibility and the severity towards the infection","volume":"12","author":"Balzanelli","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0275","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S2665-9913(20)30415-X","article-title":"Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - authors\u2019 reply","volume":"3","author":"Bovijn","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0280","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1186\/s12879-024-10073-0","article-title":"Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19","volume":"24","author":"Injinari","year":"2024","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12920-024-01911-w","article-title":"The Interleukin-6 gene variants may protect against SARS-CoV-2 infection and the severity of COVID-19: a case-control study in a Moroccan population","volume":"17","author":"Noureddine","year":"2024","journal-title":"BMC Med. Genomics"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12985-025-02668-z","article-title":"Impact of single nucleotide polymorphism of IL-27P28 rs153109 and IFITM3 rs12252 on susceptibility and severity of COVID-19 in Egyptian patients: a case control study","volume":"22","author":"Hamdy","year":"2025","journal-title":"Virol. J."},{"issue":"16","key":"10.1016\/j.bbamcr.2026.120198_bb0295","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.3390\/ijms26167668","article-title":"Cardio-pulmonary features of long COVID: from molecular and histopathological characteristics to clinical implications","volume":"26","author":"Cimmino","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0300","series-title":"Mechanisms of Lung Injury and Repair","first-page":"PA728","article-title":"Predictive systemic biomarkers of pulmonary fibrosis after COVID-19 pneumonia","author":"Suarez","year":"2021"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41593-024-01576-9","article-title":"Blood\u2013brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment","volume":"27","author":"Greene","year":"2024","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0310","doi-asserted-by":"crossref","first-page":"327","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0315","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1039\/D0LC00678E","article-title":"A digital protein microarray for COVID-19 cytokine storm monitoring","volume":"21","author":"Song","year":"2021","journal-title":"Lab Chip"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0320","unstructured":"\u201cUS National Library of Medicine, n.d. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/search?cond=covid-19&intr=il-6\u201d."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0325","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"Jones","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0330","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0335","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.13303","article-title":"Tocilizumab use in patients with moderate to severe COVID-19: a retrospective cohort study","volume":"46","author":"Chilimuri","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0340","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/joim.13162","article-title":"Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study","volume":"289","author":"Eimer","year":"2021","journal-title":"J. Intern. Med."},{"issue":"10285","key":"10.1016\/j.bbamcr.2026.120198_bb0345","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120198_bb0350","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0355","doi-asserted-by":"crossref","first-page":"100418","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study","volume":"24","author":"Kewan","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-022-01803-2","article-title":"Should we interfere with the Interleukin-6 receptor during COVID-19: what do we know so far?","volume":"83","author":"Plocque","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur. J. Intern. Med."},{"issue":"16","key":"10.1016\/j.bbamcr.2026.120198_bb0370","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0375","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1093\/cid\/ciac153","article-title":"Efficacy and safety of Sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial","volume":"75","author":"Sivapalasingam","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0380","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s40121-021-00543-2","article-title":"Efficacy and safety of Sarilumab in patients with COVID19 pneumonia: a randomized, phase III clinical trial (SARTRE study)","volume":"10","author":"Sancho-L\u00f3pez","year":"2021","journal-title":"Infect. Dis. Ther."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0385","doi-asserted-by":"crossref","first-page":"e0210721","DOI":"10.1128\/aac.02107-21","article-title":"Early use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial","volume":"66","author":"Merchante","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0390","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120198_bb0395","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0400","doi-asserted-by":"crossref","first-page":"e2295","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev. Med. Virol."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0405","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120198_bb0410","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic Interleukin-6 trans-signaling inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120198_bb0415","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2023.1084","article-title":"Effect of induction therapy with Olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial","volume":"329","author":"Zhang","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0420","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41587-021-01155-4","article-title":"A humanized mouse model of chronic COVID-19","volume":"40","author":"Sefik","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0425","doi-asserted-by":"crossref","first-page":"e0162221","DOI":"10.1128\/jvi.01622-21","article-title":"A hybrid soluble gp130\/spike-nanobody fusion protein simultaneously blocks Interleukin-6 trans-signaling and cellular infection with SARS-CoV-2","volume":"96","author":"Ettich","year":"2022","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0430","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s43556-025-00320-4","article-title":"Development of a trispecific fusion protein based on angiotensin-converting enzyme 2, glycoprotein 130, and tumor necrosis factor receptor 2 as a promising therapeutic for COVID-19","volume":"6","author":"Qiao","year":"2025","journal-title":"Mol. Biomed."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0435","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S2213-2600(21)00358-1","article-title":"Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0440","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"10349","key":"10.1016\/j.bbamcr.2026.120198_bb0445","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0450","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.2147\/JIR.S554898","article-title":"Revisiting Janus kinase inhibitors in hospitalized COVID-19: evidence for Baricitinib\u2019s superiority and the absence of a class effect","volume":"18","author":"Gu","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120198_bb0455","doi-asserted-by":"crossref","first-page":"105967","DOI":"10.1016\/j.ijantimicag.2020.105967","article-title":"Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19","volume":"55","author":"Praveen","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0460","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s12276-020-00531-5","article-title":"Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway","volume":"52","author":"Ng","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0465","doi-asserted-by":"crossref","first-page":"1220306","DOI":"10.3389\/fimmu.2023.1220306","article-title":"SARS-CoV-2 accessory proteins involvement in inflammatory and profibrotic processes through IL11 signaling","volume":"14","author":"L\u00f3pez-Ayll\u00f3n","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0470","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/0929866529666220405102230","article-title":"Mutational analysis of Interleukin-11 and its consequences on cancer and COVID-19 related cytokine storm -an extensive molecular dynamics study","volume":"29","author":"Ray","year":"2022","journal-title":"Protein Pept. Lett."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0475","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/cei\/uxad108","article-title":"Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target","volume":"214","author":"O\u2019Reilly","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1514080","article-title":"IL-6\/IL-12 superfamily of cytokines and regulatory lymphocytes play critical roles in the etiology and suppression of CNS autoimmune diseases","volume":"16","author":"Yadav","year":"2025","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.bbamcr.2026.120198_bb0485","doi-asserted-by":"crossref","first-page":"7953","DOI":"10.3390\/ijms25147953","article-title":"Role of IL-27 in COVID-19: a thin line between protection and disease promotion","volume":"25","author":"Korobova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0490","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.immuni.2012.11.003","article-title":"Interleukin-27: balancing protective and pathological immunity","volume":"37","author":"Hunter","year":"2012","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120198_bb0495","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00705-023-05792-9","article-title":"Antiviral response and immunopathogenesis of interleukin 27 in COVID-19","volume":"168","author":"Vald\u00e9s-L\u00f3pez","year":"2023","journal-title":"Arch. Virol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0500","doi-asserted-by":"crossref","first-page":"199040","DOI":"10.1016\/j.virusres.2023.199040","article-title":"American-Asian- and African lineages of Zika virus induce differential pro-inflammatory and Interleukin 27-dependent antiviral responses in human monocytes","volume":"325","author":"Hern\u00e1ndez-Sarmiento","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0505","doi-asserted-by":"crossref","first-page":"104411","DOI":"10.1016\/j.cellimm.2021.104411","article-title":"Interleukin 27 as an inducer of antiviral response against chikungunya virus infection in human macrophages","volume":"367","author":"Vald\u00e9s-L\u00f3pez","year":"2021","journal-title":"Cell. Immunol."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0510","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ajpath.2014.02.004","article-title":"IL-27R\u2013mediated regulation of IL-17 controls the development of respiratory syncytial virus\u2013associated pathogenesis","volume":"184","author":"de Almeida Nagata","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0515","doi-asserted-by":"crossref","first-page":"1385473","DOI":"10.3389\/fimmu.2024.1385473","article-title":"Interleukin 27, like interferons, activates JAK-STAT signaling and promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya viruses replication in human macrophages","volume":"15","author":"Vald\u00e9s-L\u00f3pez","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0520","doi-asserted-by":"crossref","first-page":"902853","DOI":"10.3389\/fimmu.2022.902853","article-title":"Antiviral activities of Interleukin-27: a partner for interferons?","volume":"13","author":"Amsden","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0525","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1038\/s41467-022-34895-1","article-title":"Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity","volume":"13","author":"Smith","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0530","doi-asserted-by":"crossref","first-page":"888897","DOI":"10.3389\/fimmu.2022.888897","article-title":"Dysregulated interferon response and immune hyperactivation in severe COVID-19: targeting STATs as a novel therapeutic strategy","volume":"13","author":"Eskandarian Boroujeni","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbamcr.2026.120198_bb0535","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10875-013-9923-0","article-title":"IL-27 is elevated in acute lung injury and mediates inflammation","volume":"33","author":"Xu","year":"2013","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0540","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1378\/chest.10-3297","article-title":"IL-27 is elevated in patients with COPD and patients with pulmonary TB and induces human bronchial epithelial cells to produce CXCL10","volume":"141","author":"Cao","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0545","doi-asserted-by":"crossref","first-page":"L133","DOI":"10.1152\/ajplung.00307.2015","article-title":"IL-27 enhances innate immunity of human pulmonary fibroblasts and epithelial cells through upregulation of TLR4 expression","volume":"310","author":"Su","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0550","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3889\/oamjms.2019.018","article-title":"Serum Interleukin-27 level in different clinical stages of lung cancer","volume":"7","author":"Babadi","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."},{"issue":"13","key":"10.1016\/j.bbamcr.2026.120198_bb0555","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139834","article-title":"Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease","volume":"5","author":"Zhao","year":"2020","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0560","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41419-020-03151-z","article-title":"Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients","volume":"11","author":"Angioni","year":"2020","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0565","doi-asserted-by":"crossref","first-page":"105608","DOI":"10.1016\/j.isci.2022.105608","article-title":"Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients","volume":"25","author":"Klingler","year":"2022","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0570","first-page":"396","article-title":"Serum levels of IL-21 and IL-27 do not reflect differential avidity of anti-SARS-CoV-2 IgG antibodies in symptomatic and asymptomatic COVID-19 patients","volume":"24","author":"Ebrahimpur","year":"2025","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0575","doi-asserted-by":"crossref","DOI":"10.1177\/03946320221145827","article-title":"Predicting roles of IL-27 and IL-32 in determining the severity and outcome of COVID-19","volume":"36","author":"Zamani","year":"2022","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120198_bb0580","doi-asserted-by":"crossref","first-page":"e1004110","DOI":"10.1371\/journal.ppat.1004110","article-title":"Timed action of IL-27 protects from immunopathology while preserving defense in influenza","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120198_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10092017","article-title":"HGF, IL-1\u03b1, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients","volume":"10","author":"Tamayo-Velasco","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.bbamcr.2026.120198_bb0590","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/v14091906","article-title":"Heterogenous CD8+ T cell maturation and \u2018polarization\u2019 in acute and convalescent COVID-19 patients","volume":"14","author":"Kudryavtsev","year":"2022","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120198_bb0595","first-page":"859","article-title":"Predictive value of specific cytokines for lethal COVID-19 outcome","volume":"12","author":"Arsentieva","year":"2023","journal-title":"Russian J. Infect. Immun."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0600","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7150\/ijms.67028","article-title":"Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study","volume":"19","author":"Xu","year":"2022","journal-title":"Int. J. Med. Sci."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0605","doi-asserted-by":"crossref","first-page":"114933","DOI":"10.1016\/j.celrep.2024.114933","article-title":"SARS-CoV-2 infection elucidates features of pregnancy-specific immunity","volume":"43","author":"Oh","year":"2024","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0610","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41598-023-31542-7","article-title":"Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME","volume":"13","author":"Laatifi","year":"2023","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120198_bb0615","doi-asserted-by":"crossref","first-page":"pgae327","DOI":"10.1093\/pnasnexus\/pgae327","article-title":"Immunoprofiles of COVID-19 uniquely differentiated from other viruses: a machine learning investigation of multiplex immunoassay data","volume":"3","author":"Kaur","year":"2024","journal-title":"PNAS nexus"},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0620","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1038\/s41467-023-38682-4","article-title":"Persistent serum protein signatures define an inflammatory subcategory of long COVID","volume":"14","author":"Talla","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbamcr.2026.120198_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060639","article-title":"Beneficial effects of mineralocorticoid receptor pathway blockade against endothelial inflammation induced by SARS-CoV-2 spike protein","volume":"9","author":"Jover","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.bbamcr.2026.120198_bb0630","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1084\/jem.20190173","article-title":"IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection","volume":"216","author":"Huang","year":"2019","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120198_bb0635","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.4103\/1673-5374.336134","article-title":"Exploring the role of interleukin-27 as a regulator of neuronal survival in central nervous system diseases","volume":"17","author":"Nortey","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"S1","key":"10.1016\/j.bbamcr.2026.120198_bb0640","doi-asserted-by":"crossref","first-page":"O21","DOI":"10.1186\/ar3576","article-title":"Regulation of inflammatory immune responses leading to the development of bone destructive autoimmune disease rheumatoid arthritis by IL-27","volume":"14","author":"Yoshimoto","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0645","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jdermsci.2016.11.011","article-title":"Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model","volume":"85","author":"Chen","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0650","first-page":"3565","article-title":"Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?","volume":"10","author":"Liu","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0655","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The Immunobiology of Interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0660","doi-asserted-by":"crossref","first-page":"678515","DOI":"10.3389\/fimmu.2021.678515","article-title":"Interleukin-27 and its diverse effects on bacterial infections","volume":"12","author":"Morita","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bbamcr.2026.120198_bb0665","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000005069","article-title":"Interleukin-27 promotes the generation of myeloid-derived suppressor cells to alleviate graft-versus-host disease","volume":"108","author":"Zhu","year":"2024","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.bbamcr.2026.120198_bb0670","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.4049\/jimmunol.1303435","article-title":"A soluble form of IL-27R\u03b1 is a natural IL-27 antagonist","volume":"192","author":"Dietrich","year":"2014","journal-title":"J. Immunol."},{"issue":"16_suppl","key":"10.1016\/j.bbamcr.2026.120198_bb0675","article-title":"A randomized phase 2 study of casdozokitug, an IL-27 targeting antibody, in combination with toripalimab plus bevacizumab in patients with unresectable and\/or locally advanced or metastatic hepatocellular carcinoma","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0680","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.intimp.2015.03.016","article-title":"Potent therapeutic target of inflammation, virus and tumor: focus on interleukin-27","volume":"26","author":"Duan","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0685","article-title":"An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0690","doi-asserted-by":"crossref","first-page":"1239732","DOI":"10.3389\/fimmu.2023.1239732","article-title":"The clinical relevance of OSM in inflammatory diseases: a comprehensive review","volume":"14","author":"Wolf","year":"2023","journal-title":"Front. Immunol."},{"issue":"6508","key":"10.1016\/j.bbamcr.2026.120198_bb0695","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0700","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1165\/rcmb.2021-0358OC","article-title":"Tissue proteomic analysis identifies mechanisms and stages of immunopathology in fatal COVID-19","volume":"66","author":"Russell","year":"2022","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0705","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1775044","article-title":"Plasma proteomic profile reveals persistent immune activation in post-acute sequelae of SARS-CoV-2 infection","volume":"17","author":"Fineschi","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0710","doi-asserted-by":"crossref","first-page":"1085988","DOI":"10.3389\/fmed.2023.1085988","article-title":"Biomarkers in long COVID-19: a systematic review","volume":"10","author":"Lai","year":"2023","journal-title":"Front. Med. (Lausanne)."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120198_bb0715","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41390-025-03837-0","article-title":"Distinct pro-inflammatory\/pro-angiogenetic signatures distinguish children with long COVID from controls","volume":"98","author":"Buonsenso","year":"2025","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bbamcr.2026.120198_bb0720","series-title":"Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis","author":"Ratsimandresy","year":"2025"},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020217","article-title":"Leukemia inhibitory factor: an important cytokine in pathologies and Cancer","volume":"12","author":"Jorgensen","year":"2022","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0730","doi-asserted-by":"crossref","first-page":"L550","DOI":"10.1152\/ajplung.00325.2021","article-title":"Epithelial LIF signaling limits apoptosis and lung injury during bacterial pneumonia","volume":"322","author":"Na","year":"2022","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"10","key":"10.1016\/j.bbamcr.2026.120198_bb0735","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2217\/fvl-2020-0340","article-title":"LIF and the lung\u2019s stem cell niche: is failure to use LIF to protect against COVID-19 a grave omission in managing the pandemic?","volume":"15","author":"Metcalfe","year":"2020","journal-title":"Future Virol."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120198_bb0740","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12967-025-06140-y","article-title":"Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab","volume":"23","author":"Li","year":"2025","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbamcr.2026.120198_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/biom15040600","article-title":"Sex-specific inflammatory profiles affect neuropsychiatric issues in COVID-19 survivors","volume":"15","author":"Palladini","year":"2025","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.bbamcr.2026.120198_bb0750","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cytogfr.2015.07.009","article-title":"Cardiotrophin-1: a multifaceted cytokine","volume":"26","author":"L\u00f3pez-Yoldi","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.bbamcr.2026.120198_bb0755","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/HYPERTENSIONAHA.112.194407","article-title":"Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction","volume":"60","author":"L\u00f3pez-Andr\u00e9s","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.bbamcr.2026.120198_bb0760","doi-asserted-by":"crossref","first-page":"157037","DOI":"10.1016\/j.cyto.2025.157037","article-title":"Cardiotrophin-1 as a predictor of critical COVID-19, mortality, and persistence of pulmonary fibrosis after the acute phase of infection","volume":"196","author":"\u00cd\u00f1iguez","year":"2025","journal-title":"Cytokine"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:28:53Z","timestamp":1787646533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488926000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":152,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0167488926000972"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120198","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-6 family cytokines behind acute COVID-19 and Long COVID syndrome: Mechanisms, biomarkers, and intervention strategies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120198"}}